



Transparency notification UCB SA/NV

- **Notification referring to situation on 31 December 2018**
- **Threshold crossed: 3%**
- **Latest holding: 2.88%**

Brussels (Belgium), 8 January 2019 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification with the FSMA.

The transparency notification dated 7 January 2019 has been submitted in accordance with Article 18 *juncto* Article 6 of the law of 2 May 2007 on the disclosure of large shareholdings, due to voting rights relating to voting securities of UCB SA dropping below the 3% minimum threshold (on a consolidated basis) on 31 December 2018. The variation is due to delivery of shares to employees in the framework of Long Term Incentive programs of the UCB group.

During 2018, there was no change with regard to the assimilated financial instruments included in the previous transparency notification dated 10 March 2017.

On 31 December 2018, UCB SA/NV (taking into account the holding of its affiliates) owned 5 597 184 UCB shares with voting rights (versus 6 428 833 UCB shares in its previous notification dated 10 March 2017), representing 2.88% of the total number of shares issued by the company (194 505 658) (versus 3.31% in the notification dated 10 March 2017).

2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
UCB SA/NV	Allée de la recherche 60, 1070 Brussels (Anderlecht)

- **Date on which the threshold is crossed:** 31 December 2018.
 - **Threshold crossed (in %):** 3%
-

- **Denominator:** 194 505 658.
- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
UCB SA/NV	3,684,607	2,102,356		1.08%	
UCB Fipar SA	2,744,226	3,494,828		1.80%	
Subtotal	6,428,833	5,597,184		2.88%	
TOTAL		5,597,184	0	2.88%	0.00%

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
UCB Fipar SA	options	31/03/2020	(idem)	170,840	0.09%	physical	-
UCB Fipar SA	options	31/03/2020	(idem)	264,160	0.14%	physical	+
TOTAL				435,000	0.22%		

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	6,032,184	3.10%

- **Chain of controlled undertakings through which the holding is effectively held:**
UCB SA/NV indirectly controls UCB Fipar SA.
- **Additional information:**

The disclosure obligation arose due to voting rights for UCB SA dropping below the 3% minimum threshold (on a consolidated basis). The variation is due to delivery of shares to employees in the framework of Long Term Incentive programs of the UCB group. During 2018, there was no change with regard to the assimilated financial instruments included in the previous transparency notification dated 10 March 2017.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of €4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news